Arbutus Biopharma
ABUS
ABUS
99 hedge funds and large institutions have $149M invested in Arbutus Biopharma in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
9% more funds holding
Funds holding: 91 → 99 (+8)
5.19% more ownership
Funds ownership: 29.99% → 35.18% (+5.2%)
Holders
99
Holding in Top 10
–
Calls
$13.5M
Puts
$7.71M
Top Buyers
| 1 | +$4.38M | |
| 2 | +$3.89M | |
| 3 | +$2.68M | |
| 4 |
SG Americas Securities
New York
|
+$2.57M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.15M |
Top Sellers
| 1 | -$5.34M | |
| 2 | -$1.41M | |
| 3 | -$927K | |
| 4 |
Two Sigma Advisers
New York
|
-$467K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$450K |